@ang.slater's Zepbound warnings fact-checked

What did @ang.slater actually say?

This is a comedic reverse-psychology video. @ang.slater frames weight loss benefits as fake "side effects" to drive people toward her bio link. She claims Zepbound caused her to lose 100 pounds in 11 months, eliminated food noise, regulated her PCOS cycles, improved blood pressure and cholesterol, reduced alcohol cravings, and gave her back confidence. The joke format is entertaining, but the underlying claims are real health assertions that deserve real scrutiny.

Worth noting upfront: she refers to a drug called "Agletide," which is not a real medication name. She almost certainly meant tirzepatide, the active ingredient in Zepbound. That kind of casual name-mangling in a 1.2 million view video matters, because people are searching for what they think they heard.

Does the science back this up?

More than you might expect. The core claims here are not made up. Clinical data on tirzepatide is actually quite strong, and several of her "side effects" track directly to published trial outcomes. But the framing erases a lot of real, serious adverse effects that patients absolutely should know about before starting.

The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) found tirzepatide produced mean weight loss of up to 22.5% of body weight over 72 weeks in adults with obesity. Losing 100 pounds in 11 months is at the aggressive end of that range, but not impossible depending on starting weight. The trial also documented meaningful improvements in cardiometabolic markers including blood pressure, triglycerides, and fasting glucose, which matches her claims about the pill organizer becoming unnecessary. The SURMOUNT-2 trial extended these findings to patients with type 2 diabetes.

On food noise: GLP-1 and GIP receptor agonism does appear to reduce appetite signals centrally, not just in the gut. A 2023 review by Müller et al. in Nature Metabolism described tirzepatide's dual agonism as producing stronger appetite suppression than GLP-1 single agonists, consistent with her description of food noise disappearing.

What did they get wrong (or right)?

The PCOS cycle regulation claim is the most scientifically interesting one she raised, and she gets partial credit. Insulin resistance is a major driver of cycle irregularity in PCOS, and weight loss combined with improved insulin sensitivity can restore ovulation. A 2023 study by Elkind-Hirsch et al. in Fertility and Sterility specifically examined semaglutide in PCOS patients and found improved cycle regularity. The same mechanism plausibly applies to tirzepatide, but there is no large randomized trial specifically on tirzepatide and PCOS cycles yet. So: biologically plausible, not yet definitively proven for this specific drug.

The alcohol and addiction claim is the most oversimplified. She says they "may reduce your cravings for alcohol and other addictive tendencies" as if it is a given. The evidence here is early and mixed. A 2023 study by Klausen et al. in JCI Insight found GLP-1 receptor agonists reduced alcohol intake in rodent models, and some case reports and small human studies suggest reduced cravings. But this is not an approved indication, the mechanism in humans is not established, and presenting it as a casual bonus effect is irresponsible at a 1.2 million view scale.

What she got completely wrong by omission: nausea, vomiting, diarrhea, and constipation affect a significant portion of tirzepatide users, particularly during dose escalation. The SURMOUNT-1 trial reported gastrointestinal adverse events in over 60% of participants. There is also a boxed warning for thyroid C-cell tumors in animal studies. None of that makes it into the joke.

What should you actually know?

The benefits she describes are real and documented. Tirzepatide is one of the most effective weight loss agents studied in a clinical trial setting, and the downstream cardiometabolic improvements are not trivial. For people managing obesity-related conditions, these are meaningful outcomes.

But this video is structured as a sales funnel. The last line tells you not to click the link in her bio while obviously inviting you to do exactly that. That framing, combined with the "side effects" joke, strips away the context that makes informed consent possible.

If you are considering a GLP-1 medication, the conversation should include: your personal history of pancreatitis, thyroid cancer, or MEN2 syndrome; a realistic picture of GI side effects during titration; the fact that muscle mass loss can accompany rapid weight loss without adequate protein intake and resistance training; and what happens when you stop the medication, because weight regain is common without ongoing treatment or lifestyle infrastructure. A licensed provider, not a TikTok bio link, is where that conversation belongs.

Bottom line on @ang.slater's claims

She is not making things up. The cardiometabolic benefits, appetite suppression, and PCOS cycle effects all have real scientific backing. Her personal result is dramatic but within the range of what trials have shown. The problem is the omission of genuine risks and the commercial structure wrapped around legitimate health information. Entertaining content. Incomplete health guidance.